^
Association details:
Biomarker:MTOR M2327I
Cancer:Breast Cancer
Drug:RapaLink-1 (mTOR inhibitor, mTORC1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor

Excerpt:
RapaLink-1 at low doses (3–10 nM) was the only drug regimen capable of inhibiting mTOR signaling in both F2108L mTOR and M2327I mTOR expressing cells (Figures 4a, b).
DOI:
10.1038/nature17963